PT  - JOURNAL ARTICLE
AU  - Golding, Nick
AU  - Price, David J.
AU  - Ryan, Gerard E.
AU  - McVernon, Jodie
AU  - McCaw, James M.
AU  - Shearer, Freya M.
TI  - Estimating the transmissibility of SARS-CoV-2 during periods of high, low and zero case incidence
AID  - 10.1101/2021.11.28.21264509
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.11.28.21264509
4099  - http://medrxiv.org/content/early/2021/11/29/2021.11.28.21264509.short
4100  - http://medrxiv.org/content/early/2021/11/29/2021.11.28.21264509.full
AB  - Against a backdrop of widespread global transmission, a number of countries have successfully brought large outbreaks of COVID-19 under control and maintained near-elimination status. A key element of epidemic response is the tracking of disease transmissibility in near real-time. During major outbreaks, the reproduction rate can be estimated from a time-series of case, hospitalisation or death counts. In low or zero incidence settings, knowing the potential for the virus to spread is a response priority. Absence of case data means that this potential cannot be estimated directly.We present a semi-mechanistic modelling framework that draws on time-series of both behavioural data and case data (when disease activity is present) to estimate the transmissibility of SARS-CoV-2 from periods of high to low – or zero – case incidence, with a coherent transition in interpretation across the changing epidemiological situations. Of note, during periods of epidemic activity, our analysis recovers the effective reproduction number, while during periods of low – or zero – case incidence, it provides an estimate of transmission risk. This enables tracking and planning of progress towards the control of large outbreaks, maintenance of virus suppression, and monitoring the risk posed by re-introduction of the virus.We demonstrate the value of our methods by reporting on their use throughout 2020 in Australia, where they have become a central component of the national COVID-19 response.Competing Interest StatementThe authors of this manuscript are contracted by the Australian Government Department of Health to provide epidemiological analysis to support the COVID-19 response. James McCaw and Jodie McVernon are invited expert members of the Australian Health Protection Principal Committee.Funding StatementThis work was directly funded by the Australian Government Department of Health Office of Health Protection. Additional support was provided by the Australian Research Council (NG DECRA fellowship DE180100635) and the National Health and Medical Research Council of Australia through its Centres of Research Excellence (SPECTRUM, GNT1170960) and Investigator Grant Schemes (JMcV Principal Research Fellowship, GNT1117140).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was undertaken as urgent public health action to support Australia's COVID-19 pandemic response. The study used data from the Australian National Notifiable Disease Surveillance System (NNDSS) provided to the Australian Government Department of Health under the National Health Security Agreement for the purposes of national communicable disease surveillance. Data from the NNDSS were supplied after de-identification to the investigator team for the purposes of provision of epidemiological advice to government. Contractual obligations established strict data protection protocols agreed between the University of Melbourne and sub-contractors and the Australian Government Department of Health, with oversight and approval for use in supporting Australia's pandemic response and for publication provided by the data custodians represented by the Communicable Diseases Network of Australia. The ethics of the use of these data for these purposes, including publication, was agreed by the Department of Health with the Communicable Diseases Network of Australia.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe analyses performed in the manuscript required access to epidemiological data provided through the Australian National Notifiable Disease Surveillance System (NNDSS), which is not able to be shared under the terms of our data access agreement. Further information on the NNDSS, including how to request access to data from the Australian Government Department of Health, is available at: https://www1.health.gov.au/internet/main/publishing.nsf/Content/ohp-pub-datasets.htm